Respiratory tract delivery of interferon-tau

Methods for treating systemic or local diseases or conditions by administering an interferon as therapeutic agent to one or several regions of the respiratory tract are provided. In one embodiment, the interferon is interferon-tau.

CP Liu - US

Recombinant human interferon-like proteins

This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison ...

H Wang，C Mao，J Li，...

Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same

The present invention is directed to pharmaceutical compositions comprising prasugrel and a cyclodextrin derivative, and methods of making and using the same.

GL Mosher，SG Machatha，DJ Cushing - US

RECOMBINANT HUMAN INTERFERON-LIKE PROTEIN

PROBLEM TO BE SOLVED: To provide a novel interferon-like protein having increased biological activity.SOLUTION: There is provided a non-naturally occurring protein having human interferon-like biological activities, the protein being sel...

H Wang，ワン,ハイタオ，C Mao，...

Interferon beta-like molecules for treatment of cancer

The present invention relates to interferon beta (IFNB) polypeptides with an increased half-life in the treatment of various cancers, in particular solid tumors. More particularly, the present invention is directed to a method of treatin...

POUL SORENSEN

METHOD OF STABILIZING PROTEIN

It is found out that deamidation of an antibody can be inhibited without affecting the activity of the antibody by substituting glycine adjacent to asparag...

Sugo, Izumi c/o CHUGAI SEIYAKU KABUSHIKI KAISHA，Tomonou, Kikuo c/o CHUGAI SEIYAKU KABUSHIKI KAISHA

RESPIRATORY TRACT DELIVERY OF INTERFERON-TAU

Methods for treating systemic or local diseases or conditions by administering an interferon as therapeutic agent to one or several regions of the respiratory tract are provided. In one embodiment, the interferon is interferon-tau.

CP Liu - US

C-terminally truncated interferon alpha variants

The present invention provides biologically active variants of human α-2b-interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human α-2b-interferon. It is the novel fi...

L Dickey，J Gasdaska，K Cox

PEG-INTERFERON-BETA FORMULATIONS

PROBLEM TO BE SOLVED: To provide pegylated-interferon-&bgr; (PEG-IFN-&bgr;) formulations.SOLUTION: A stabilized liquid pharmaceutical composition comprises PEG-IFN-&bgr; or its mutein or active fragment thereof, a polyol excipient of man...

AD Rio，デル リオ,アレッサンドラ，J Richard，...

RECOMBINANT HUMAN INTERFERON-LIKE PROTEINS

PROBLEM TO BE SOLVED: To provide novel interferon-like proteins having enhanced biological activities.SOLUTION: Provided is a non-naturally occurring protein having human interferon-like biological activities, wherein the protein is sele...

H Wang，ワン,ハイタオ，C Mao，...